UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Journal of the American Heart Association, 2020-07, Vol.9 (13), p.e017559

2020

Volltextzugriff (PDF)

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Journal of thrombosis and haemostasis, 2020-06, Vol.18 (6), p.1320-1323

2020

Volltextzugriff (PDF)

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial

Journal of the American Society of Nephrology, 2021-06, Vol.32 (6), p.1474-1483

2021

Volltextzugriff (PDF)

Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States

Circulation (New York, N.Y.), 2018-10, Vol.138 (15), p.1519-1529

2018

Volltextzugriff (PDF)

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

Journal of the American College of Cardiology, 2020-06, Vol.75 (25), p.3122-3135

2020

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.628-636

2016

Volltextzugriff (PDF)

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial

Circulation (New York, N.Y.), 2016-07, Vol.134 (1), p.24-36

2016

Volltextzugriff (PDF)

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2018-09, Vol.16 (9), p.1891-1894

2018

Volltextzugriff (PDF)

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation (New York, N.Y.), 2023-03, Vol.147 (13), p.1026-1038

2023

Volltextzugriff (PDF)

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.637-645

2016

Volltextzugriff (PDF)

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2119-2126

2015

Volltextzugriff (PDF)

Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

Circulation (New York, N.Y.), 2016-07, Vol.134 (3), p.248-261

2016

Volltextzugriff (PDF)

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Circulation (New York, N.Y.), 2015-01, Vol.131 (1), p.82-90

2015

Volltextzugriff (PDF)

Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

European heart journal, 2014-12, Vol.35 (47), p.3346-3355

2014

Volltextzugriff (PDF)

Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus

Journal of the American College of Cardiology, 2020-04, Vol.75 (14), p.1676-1685

2020

Volltextzugriff (PDF)

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

European heart journal, 2014-07, Vol.35 (28), p.1864-1872

2014

Volltextzugriff (PDF)

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2019-10, Vol.17 (10), p.1772-1778

2019

Volltextzugriff (PDF)

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Journal of thrombosis and haemostasis, 2015-12, Vol.13 (12), p.2187-2191

2015

Volltextzugriff (PDF)

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Circulation (New York, N.Y.), 2017-03, Vol.135 (13), p.1273-1275

2017

Volltextzugriff (PDF)

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF

Circulation (New York, N.Y.), 2016-07, Vol.134 (1), p.37-47

2016

Volltextzugriff (PDF)

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

Circulation (New York, N.Y.), 2016-01, Vol.133 (4), p.352-360

2016

Volltextzugriff (PDF)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Journal of the American Heart Association, 2016-06, Vol.5 (6), p.n/a

2016

Volltextzugriff (PDF)

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

European heart journal, 2015-05, Vol.36 (20), p.1264-1272

2015

Volltextzugriff (PDF)

Bleeding incidence and risk factors among cancer patients treated with anticoagulation

American journal of hematology, 2019-07, Vol.94 (7), p.780-785

2019

Volltextzugriff (PDF)

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

European heart journal, 2014-07, Vol.35 (28), p.1873-1880

2014

Volltextzugriff (PDF)

1 – 25 von 1.585

Suche als RSS-Feed

Aktive Filter

KollektionPublisher or Other Site

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.456)
Mit Volltextzugriff
(1.201)

Publikationsform

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.543)
Science & Technology
(1.354)
Life Sciences & Biomedicine
(1.331)
Factor Xa Inhibitors - Adverse Effects
(842)
Male
(778)
Female
(735)
Anticoagulants - Adverse Effects
(726)
Cardiovascular System & Cardiology
(722)
Hemorrhage - Chemically Induced
(616)
Aged
(610)
Middle Aged
(527)
Anticoagulants
(486)
Treatment Outcome
(474)
Factor Xa Inhibitors
(468)
Cardiac & Cardiovascular Systems
(467)
Factor Xa Inhibitors - Therapeutic Use
(463)
Administration, Oral
(445)
Factor Xa Inhibitors - Administration & Dosage
(428)
Anticoagulants - Therapeutic Use
(424)
Rivaroxaban
(423)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.579)
Journals@Ovid Full Text
(779)
Ingenta
(721)
EZB Electronic Journals Library
(681)
IngentaConnect Journals
(460)
Elsevier ScienceDirect Journals Complete
(295)
Wiley-Blackwell Journals
(244)
Springer Online Journals Complete
(222)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(181)
Wiley Online Library
(179)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(151)
Access via Taylor & Francis
(84)
SAGE Publications
(76)
Taylor & Francis
(71)
Oxford Journals
(58)
Oxford Journals 2020 Medicine
(53)
Taylor & Francis Online
(48)
BMJ
(42)
Thieme Connect
(39)
Nexis Uni
(32)
Publisher website
(0)

16 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(22)
... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial

Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

Bleeding incidence and risk factors among cancer patients treated with anticoagulation

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

Aktive Filter

Suchergebnisse filtern